Borderline Product Determination for Medical Devices in Singapore

1. Key takeaways

In Singapore, whether a product is a medical device depends on its intended use, not its physical form. Pure lifestyle or health-promotion products — body shaping devices, massage devices, magnetic jewellery, and wellness telehealth apps carrying a non-medical designation — are generally not determined to be medical devices. But this exclusion is fragile: once disease-related prevention, relief or cure claims enter the labelling, instructions or promotion, the intended use shifts, and the product may be re-determined as a medical device, triggering registration obligations. The determination is therefore a compliance question about words, not a technical question about hardware, and it deserves the same rigour as any other regulatory assessment.

• Intended use is carried by documents and wording, not only by the label.
• Software borderline products are judged almost entirely by their claims (GL-04 R4; GL-07 R2).
• A non-device determination should itself be documented, or it cannot be defended.
• Borderline products can still be caught by advertising rules for other health product categories.

2. Legal basis

The determination framework rests on the Health Products Act 2007 and the classification and software guidance instruments summarised below.

We apply a four-question framework to each product; the path through the questions determines the leaning of the determination.

3. Expert insights

Five points explain where borderline determinations succeed or fail.

Insight 1: intended use is carried by documents plus wording, not only by the label. In our reviews we examine three classes of material together: product labelling and instructions, official websites and e-commerce pages, and sales scripts and training materials. Where the three diverge, a regulator can determine the intended use from any one of them — and in practice the divergence usually comes from marketing copy that nobody checked against the regulatory position. A single marketing sentence claiming support for improving diabetes is enough to turn a wellness product into a medical device, no matter what the label says.

Insight 2: software borderline products are decided almost entirely by their claims. Whether an app is SaMD depends almost wholly on what it claims to do, which makes the claims language the decisive evidence in the assessment. GL-04 R4 and GL-07 R2 provide the determination framework, while wellness telehealth apps without medical claims are generally excluded. Our practice on projects is to write the explicit non-medical-use designation into the product interface and its documentation, so the exclusion is visible to both users and reviewers.

Insight 3: even a non-device determination needs written evidence. HSA can challenge a determination. An internal determination record — citing the specific provisions and recording the reasoning — is highly useful during customs checks or HSA queries, and it protects the company against internal turnover, since the person who made the call may not be there when the question is asked again. An undocumented determination is no determination at all.

Insight 4: borderline products can still be caught by advertising rules. This point is easily missed: even where a product is not a medical device, promotion touching health claims may fall under the advertising regulation of other health product categories. Singapore maintains separate advertising rules for each health product category; being determined a non-device does not mean freedom in marketing. Promotional content should therefore pass the category-specific advertising review even while the device determination itself is still open.

Insight 5: once the determination flips, the obligations cascade. Moving from non-device to medical device triggers a chain: product registration (or product notification) plus dealer licensing plus vigilance obligations plus advertising restrictions plus UDI (depending on class). This is not adding one task; it is adding an entire system, and the timing rarely leaves room to build it calmly.

4. Practical recommendations

We recommend the following measures for portfolios containing lifestyle or wellness products.

1. Run the four-question framework per product and produce a determination file, and archive it together with the evidence consulted.
2. Align the three classes of material: labelling, website and sales scripts, so no single document drifts from the determination.
3. Mark software products explicitly as non-medical-use, in the interface and the documentation.
4. Keep reviewing promotional content even after a non-device determination, to avoid other categories’ advertising rules.
5. Re-determine when the product line expands: new functions and claims can change the determination.

Regulatory information verified as of: 26 October 2026

Source level: Tier 1 (Health Products Act 2007), Tier 2 (GL-06 R2; GN-13 R2.1; GL-04 R4; GL-07 R2; GN-08)

5. Verification checklist

• □ A written determination file exists for every product
• □ Labelling, instructions, website and sales scripts are consistent
• □ Software products carry an explicit non-medical-use designation
• □ SMDR has been searched for similar products’ determinations as corroboration
• □ Promotional content has been reviewed, even where the determination is non-device
• □ Re-determination is planned when the product line expands
• □ Determination files cite the specific provisions relied on

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com